Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor.

13 , 23 , 37 , 39 Orally administered HM5023507 attenuated the neutrophil chemotaxis in a dose‐related manner (Figure 4 ), with a clear trend for reduction seen at a dose of 3 mg/kg (p.o.) and a reduction to baseline levels at 10 mg/kg ( P < .05).

also in 19,460 other papers